# Bracco reports 6 million global doses of VUEWAY gadopiclenol MRI contrast injection

> Diagnostic imaging company Bracco announced that more than 6 million intravenous doses of VUEWAY (gadopiclenol) have been administered worldwide since its initial 2022 approval, following 2026 EU and U.S. pediatric extensions to term neonates and infants. The release also highlights the Max 3 injector and AiMIFY software, without disclosing product sales revenue.

- Canonical URL: https://newsverum.com/en/news/bracco-reaches-6-million-vueway-gadopiclenol-mri-contrast-doses-2026
- Publisher: Newsverum
- Section: Health
- Country: United States
- Published: 2026-11-20T17:39:59+00:00
- Updated: 2026-11-20T17:39:59+00:00
- Event / data period: 2026-11-20
- Other editions: [Türkçe](https://newsverum.com/tr/news/bracco-reaches-6-million-vueway-gadopiclenol-mri-contrast-doses-2026.md), [العربية](https://newsverum.com/ar/news/bracco-reaches-6-million-vueway-gadopiclenol-mri-contrast-doses-2026.md), [Français](https://newsverum.com/fr/news/bracco-reaches-6-million-vueway-gadopiclenol-mri-contrast-doses-2026.md), [Español](https://newsverum.com/es/news/bracco-reaches-6-million-vueway-gadopiclenol-mri-contrast-doses-2026.md), [Deutsch](https://newsverum.com/de/news/bracco-reaches-6-million-vueway-gadopiclenol-mri-contrast-doses-2026.md), [Português](https://newsverum.com/pt/news/bracco-reaches-6-million-vueway-gadopiclenol-mri-contrast-doses-2026.md)

Diagnostic imaging company Bracco announced in Princeton, New Jersey, on 20 November 2026 that more than 6 million doses of VUEWAY (gadopiclenol) intravenous injection have been administered worldwide. First approved by regulators in 2022, VUEWAY is a macrocyclic gadolinium-based contrast agent used in magnetic resonance imaging to detect and visualize lesions with abnormal vascularity across the central nervous system—including the brain, spine, and associated tissues—as well as the head, neck, thorax, abdomen, pelvis, and musculoskeletal system. While the 6-million-dose figure tracks cumulative global clinical utilization over a four-year period, the announcement does not disclose unit sales revenue, geographic dose breakdowns, or market-share percentages.

VUEWAY is formulated to deliver diagnostic contrast enhancement at a gadolinium dose of 0.05 millimoles per kilogram of body weight, which corresponds to half the standard 0.1 millimoles per kilogram dose used by conventional gadolinium-based contrast agents. According to Cosimo De Pinto, Executive Vice President of Marketing and Commercial Operations at Bracco Americas, the macrocyclic molecular design provides the highest relaxivity per gadolinium ion among U.S. Food and Drug Administration-approved gadolinium contrast agents with comparable indications, enabling lower cumulative gadolinium exposure for patients who require repeated imaging scans.

During 2026, regulatory authorities in both the European Union and the United States expanded the approved pediatric labeling of VUEWAY to cover term neonates and infants alongside older children and adults. Extending the indication to the youngest pediatric cohorts broadens hospital eligibility for low-dose contrast-enhanced magnetic resonance imaging, though the company's release does not report how many of the 6 million cumulative doses were administered to pediatric or neonatal patients.

Alongside the contrast agent milestone, Bracco highlighted two complementary hardware and software systems within its magnetic resonance imaging workflow portfolio. The first is the ulricheasyINJECT Max 3 (model XD 10180), a cable-free, closed-system, syringeless rapid-exchange magnetic resonance injector distributed by Bracco Diagnostics Inc. Featuring automatic air detection, particle filtration, and SafeConnect touch protection, the Max 3 injector received an expanded U.S. indication permitting its use with the multi-patient VUEWAY Imaging Bulk Package in addition to single-dose vials, prefilled syringes, and pharmacy bulk packages.

The second portfolio component highlighted by the company is AiMIFY, an artificial-intelligence software application developed in partnership with Subtle Medical. AiMIFY is designed to amplify existing contrast enhancement in post-contrast brain magnetic resonance images to assist radiologists in visualizing enhancing lesions, and was named Best New Radiology Software in AuntMinnie.com's 2026 Minnies Awards. Pairing a lower-dose macrocyclic agent with automated multi-dose injectors and post-processing software reflects an industry strategy to bundle contrast consumables with imaging department hardware and workflow software.

In its mandatory prescribing and safety disclosures, Bracco reiterated the class-wide boxed warning applicable to gadolinium-based contrast agents. VUEWAY is strictly contraindicated for intrathecal administration—which can cause fatal or severe reactions including coma, encephalopathy, and seizures—and carries a boxed warning for nephrogenic systemic fibrosis in patients with impaired drug elimination. The risk of nephrogenic systemic fibrosis is highest in patients with acute kidney injury or chronic, severe kidney disease defined by a glomerular filtration rate below 30 milliliters per minute per 1.73 square meters of body surface area.

Clinical trial safety data included in the prescribing summary note that gadolinium can be retained for months or years in bone, brain, skin, kidney, liver, and spleen tissue following administration, and that acute kidney injury requiring dialysis has occurred in patients with chronically reduced renal function. In clinical studies, the most common adverse reactions occurring at an incidence of 0.5 percent or higher were injection-site pain at 0.7 percent and headache at 0.7 percent, while post-marketing surveillance across gadolinium agents has recorded rare cases of acute pancreatitis within 48 hours of dosing, acute respiratory distress syndrome, pulmonary edema, and gadolinium-associated skin plaques.

Manufactured for Bracco Diagnostics Inc. by BIPSO GmbH in Singen, Germany, VUEWAY's passage beyond 6 million administered doses confirms sustained clinical adoption since its 2022 launch and 2026 neonatal label expansion. Evaluating the commercial impact of that milestone would require financial disclosures on contrast media revenue, hospital adoption rates for the Max 3 Imaging Bulk Package configuration, and clinical outcome studies comparing AI-amplified brain MRI against standard protocols.

## Data

### Key reported figures

Selected figures transcribed from the cited primary source.

Methodology: Figures retain the source's stated period, scope and definitions. Announced targets, estimates and approximate figures are labeled by basis and qualifier. No missing value is inferred.

| label | value | unit | period | basis | value_qualifier |
|---|---|---|---|---|---|
| Cumulative VUEWAY (gadopiclenol) injection doses administered worldwide | 6000000 | doses | 2026-11-20 | observed | lower-bound |
| Clinical trial incidence of injection-site pain with VUEWAY | 0.7 | percent | 2026-11-20 | observed |  |
| Clinical trial incidence of headache with VUEWAY | 0.7 | percent | 2026-11-20 | observed |  |

Sources: <https://www.prnewswire.com/news-releases/bracco-delivers-6-million-vueway-gadopiclenol-injection-doses-worldwide-as-its-mri-portfolio-continues-to-evolve-302947069.html> · Download data: [JSON](https://newsverum.com/api/v1/articles/bracco-reaches-6-million-vueway-gadopiclenol-mri-contrast-doses-2026/data/reported-figures?lang=en&format=json) · [CSV](https://newsverum.com/api/v1/articles/bracco-reaches-6-million-vueway-gadopiclenol-mri-contrast-doses-2026/data/reported-figures?lang=en&format=csv)

## Sources

- [Bracco Diagnostics, Bracco Delivers 6 Million VUEWAY (gadopiclenol) Injection Doses Worldwide as Its MRI Portfolio Continues to Evolve](<https://www.prnewswire.com/news-releases/bracco-delivers-6-million-vueway-gadopiclenol-injection-doses-worldwide-as-its-mri-portfolio-continues-to-evolve-302947069.html>) (Source checked: 2026-11-20; Published: 2026-11-20)

---

Cite the canonical URL above. [Editorial standards and corrections](https://newsverum.com/en/editorial)
